Clinical Cancer Research, Vol 1, Issue 10 1079-1087, Copyright © 1995 by American Association for Cancer Research

ARTICLES

Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer

J Grondahl-Hansen, HA Peters, WL van Putten, MP Look, H Pappot, E Ronne, K Dano, JG Klijn, N Brunner and JA Foekens
Finsen Laboratory, Rigshospitalet, Strandboulevarden 49, DK-2100 Copenhagen, Denmark.

We have recently described the urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) as strong prognostic variables in breast cancer (J. A. Foekens et al., Cancer Res., 52: 6101-6105, 1992; J. Grondahl-Hansen et al., Cancer Res., 53: 2513-2521, 1993; J. A. Foekens et al., J. Clin. Oncol., 11: 899-908, 1994). A specific cell surface receptor (uPAR) binds uPA and strongly enhances plasmin generation, and the amount of uPAR in the tumor tissue might therefore be a rate-limiting factor in the extracellular proteolysis involved in tumor invasion. Here, we report on the prognostic value of uPAR in cytosolic (uPARc) and Triton (uPARt) extracts prepared from 505 primary breast tumors. The median observation time was 54 (range: 12-125) months. uPAR levels were determined by a sandwich ELISA. Univariate analysis showed that high uPAR levels (above the median value) were significantly associated with a shorter overall survival, showing a stronger discriminatory effect for uPARc [relative hazard rate (RHR): 1.47; P = 0.012)] as compared with uPARt (RHR, 1.33; P = 0.059), while no statistically significant differences were found for relapse-free survival. Multivariate analysis including all patients showed that when including other biochemical variables (estrogen receptor, progesterone receptor, PS2, cathepsin D, uPA, and PAI-1), the only retained independent variable via backward elimination was PAI-1 for both relapse-free survival and overall survival. When analyzed separately in clinically relevant subgroups, the prognostic value of uPAR was particularly strong in a subgroup of 201 node-positive postmenopausal women, showing considerably shorter overall (RHR: 2.39; P < 0.0001) and relapse free (RHR: 1.91; P = 0.0006) survival for patients with high uPARc content. High uPARt levels were also significantly associated with shorter overall survival in this subgroup of patients (RHR: 1.5; P = 0.047), but not with relapse-free survival (P = 0.64). Multivariate analysis, including the basic model, estrogen and progesterone receptors, PS2, cathepsin D, uPA, PAI-1, uPARc, and uPARt in the subgroup of postmenopausal node-positive patients, showed that only uPARc and PAI-1 were significant independent prognostic parameters, with respect to overall survival, RHRs being 2.72 (P < 0.0001) and 1.81 (P = 0.005), respectively. In multivariate analysis of relapse-free survival, uPARc, PAI-1, and uPA were independent parameters with respective relative relapse rates of 1.91 (P = 0.002) for uPARc, 1.68 (P = 0.02) for PAI-1, and 1.6 (P = 0.03) for uPA. These data lend support to the hypothesis that uPAR is an important molecule in plasmin-mediated extracellular matrix degradation leading to cancer cell dissemination and death of the patient.

This article has been cited by other articles:

				S. Meng, D. Tripathy, S. Shete, R. Ashfaq, H. Saboorian, B. Haley, E. Frenkel, D. Euhus, M. Leitch, C. Osborne, et al. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues PNAS, November 14, 2006; 103(46): 17361 - 17365. [Abstract] [Full Text] [PDF]

				T. Piironen, A. Haese, H. Huland, T. Steuber, I. J. Christensen, N. Brunner, K. Dano, G. Hoyer-Hansen, and H. Lilja Enhanced Discrimination of Benign from Malignant Prostatic Disease by Selective Measurements of Cleaved Forms of Urokinase Receptor in Serum Clin. Chem., May 1, 2006; 52(5): 838 - 844. [Abstract] [Full Text] [PDF]

				T. Piironen, B. Laursen, J. Pass, K. List, H. Gardsvoll, M. Ploug, K. Dano, and G. Hoyer-Hansen Specific Immunoassays for Detection of Intact and Cleaved Forms of the Urokinase Receptor Clin. Chem., November 1, 2004; 50(11): 2059 - 2068. [Abstract] [Full Text] [PDF]

				M. E. M.-v. Gelder, M. P. Look, H. A. Peters, M. Schmitt, N. Brunner, N. Harbeck, J. G. M. Klijn, and J. A. Foekens Urokinase-Type Plasminogen Activator System in Breast Cancer: Association with Tamoxifen Therapy in Recurrent Disease Cancer Res., July 1, 2004; 64(13): 4563 - 4568. [Abstract] [Full Text] [PDF]

				R. Riisbro, I. J. Christensen, T. Piironen, M. Greenall, B. Larsen, R. W. Stephens, C. Han, G. Hoyer-Hansen, K. Smith, N. Brunner, et al. Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Serum and Cytosol of Tumor Tissue from Patients with Primary Breast Cancer Clin. Cancer Res., May 1, 2002; 8(5): 1132 - 1141. [Abstract] [Full Text] [PDF]

				D. A. Vallera, C. Li, N. Jin, A. Panoskaltsis-Mortari, and W. A. Hall Targeting Urokinase-Type Plasminogen Activator Receptor on Human Glioblastoma Tumors With Diphtheria Toxin Fusion Protein DTAT J Natl Cancer Inst, April 17, 2002; 94(8): 597 - 606. [Abstract] [Full Text] [PDF]

				J. Vakili, L. Standker, M. Detheux, G. Vassart, W.-G. Forssmann, and M. Parmentier Urokinase Plasminogen Activator and Plasmin Efficiently Convert Hemofiltrate CC Chemokine 1 into Its Active [9-74] Processed Variant J. Immunol., September 15, 2001; 167(6): 3406 - 3413. [Abstract] [Full Text] [PDF]

				G. van der Pluijm, B. Sijmons, H. Vloedgraven, C. van der Bent, J.-W. Drijfhout, J. Verheijen, P. Quax, M. Karperien, S. Papapoulos, and C. Lowik Urokinase-Receptor/Integrin Complexes Are Functionally Involved in Adhesion and Progression of Human Breast Cancer in Vivo Am. J. Pathol., September 1, 2001; 159(3): 971 - 982. [Abstract] [Full Text] [PDF]

				N. Harbeck, U. Alt, U. Berger, A. Kruger, C. Thomssen, F. Janicke, H. Hofler, R. E. Kates, and M. Schmitt Prognostic Impact of Proteolytic Factors (Urokinase-Type Plasminogen Activator, Plasminogen Activator Inhibitor 1, and Cathepsins B, D, and L) in Primary Breast Cancer Reflects Effects of Adjuvant Systemic Therapy Clin. Cancer Res., September 1, 2001; 7(9): 2757 - 2764. [Abstract] [Full Text] [PDF]

				P. O. Chappuis, B. Dieterich, V. Sciretta, C. Lohse, H. Bonnefoi, S. Remadi, and A.-P. Sappino Functional Evaluation of Plasmin Formation in Primary Breast Cancer J. Clin. Oncol., May 15, 2001; 19(10): 2731 - 2738. [Abstract] [Full Text] [PDF]

				H. Solberg, M. Ploug, G. Høyer–Hansen, B. S. Nielsen, and L. R. Lund The Murine Receptor for Urokinase-Type Plasminogen Activator Is Primarily Expressed in Tissues Actively Undergoing Remodeling J. Histochem. Cytochem., February 1, 2001; 49(2): 237 - 246. [Abstract] [Full Text]

				N. C. Denko and A. J. Giaccia Tumor Hypoxia, the Physiological Link between Trousseau's Syndrome (Carcinoma-induced Coagulopathy) and Metastasis Cancer Res., February 1, 2001; 61(3): 795 - 798. [Full Text]

				A. N. Pedersen, I. J. Christensen, R. W. Stephens, P. Briand, H. T. Mouridsen, K. Danø, and N. Brünner; The Complex between Urokinase and Its Type-1 Inhibitor in Primary Breast Cancer: Relation to Survival Cancer Res., December 1, 2000; 60(24): 6927 - 6934. [Abstract] [Full Text]

				M. N. Holten-Andersen, R. W. Stephens, H. J. Nielsen, G. Murphy, I. J. Christensen, W. Stetler-Stevenson, and N. Brunner High Preoperative Plasma Tissue Inhibitor of Metalloproteinase-1 Levels Are Associated with Short Survival of Patients with Colorectal Cancer Clin. Cancer Res., November 1, 2000; 6(11): 4292 - 4299. [Abstract] [Full Text] [PDF]

				R. IPPOLITI, E. LENDARO, P. A. BENEDETTI, M. R. TORRISI, F. BELLEUDI, D. CARPANI, M. R. SORIA, and M. S. FABBRINI Endocytosis of a chimera between human pro-urokinase and the plant toxin saporin: an unusual internalization mechanism FASEB J, July 1, 2000; 14(10): 1335 - 1344. [Abstract] [Full Text]

				J. A. Foekens, H. A. Peters, M. P. Look, H. Portengen, M. Schmitt, M. D. Kramer, N. Brünner, F. Jänicke, M. E. M.-v. Gelder, S. C. Henzen-Logmans, et al. The Urokinase System of Plasminogen Activation and Prognosis in 2780 Breast Cancer Patients Cancer Res., February 1, 2000; 60(3): 636 - 643. [Abstract] [Full Text]

				R. W. Stephens, H. J. Nielsen, I. J. Christensen, O. Thorlacius-Ussing, S. Sorensen, K. Dano, and N. Brunner Plasma Urokinase Receptor Levels in Patients With Colorectal Cancer: Relationship to Prognosis J Natl Cancer Inst, May 19, 1999; 91(10): 869 - 874. [Abstract] [Full Text] [PDF]

				S Suzuki, Y Hayashi, Y Wang, T Nakamura, Y Morita, K Kawasaki, K Ohta, N Aoyama, S R Kim, H Itoh, et al. Urokinase type plasminogen activator receptor expression in colorectal neoplasms Gut, December 1, 1998; 43(6): 798 - 805. [Abstract] [Full Text] [PDF]

				R. W. Stephens, A. N. Pedersen, H. J. Nielsen, M. J. A. G. Hamers, G. Hoyer-Hansen, E. Ronne, E. Dybkjær, K. Dano, and N. Brunner ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients Clin. Chem., October 1, 1997; 43(10): 1868 - 1876. [Abstract] [Full Text] [PDF]